Skip to main content
Figure 6 | BMC Biotechnology

Figure 6

From: Human TGFalpha-derived peptide TGFalphaL3 fused with superantigen for immunotherapy of EGFR-expressing tumours

Figure 6

The antigenicity evaluation of TGFαL3SEA D227A . Nine mice were randomised into three groups and injected intramuscularly with 1 mg TGFαL3SEAD227A, rSEA, or PBS, respectively. The injections were repeated three times at two-week intervals. Then serum from each group was collected and analysed as follows. (A) To detect the antigenicity of TGFαL3SEAD227A (square) or rSEA (triangle), the corresponding proteins were coated on ELISA plates. The titres of antibody were detected in the standard way. (B) To analyse the antigen epitopes recognised by the TGFαL3SEAD227A antibody, the native ligand TGFα (square), rSEA (triangle), or BSA(circle)was coated and the anti-serum of TGFαL3SEAD227A was analysed in the same way as (A).

Back to article page